In particular, immune checkpoint inhibitors such as programmed cell death protein 1 (PD-1) inhibitors are demonstrating an increased overall survival and progression-free survival (OS and PFS) in patients with metastatic melanoma (MM) (2–5). This evidence concerns the gene PDCD1 and Miyoshi myopathy.